CCL2 and acute kidney injury: WB analysis showed that JPYSF can exert anti-inflammatory effect in cisplatin-induced AKI by reducing the expression of pro-inflammatory cytokines, such as IL-6, TNF-α and MCP-1 and increasing the expression of anti-inflammatory factor IL-10.